Cladribine Shortage Update: What Patients Need to Know in 2026

The Cladribine Access Problem in 2026

If you've been searching for Cladribine and coming up empty, you might be wondering: is there a shortage? The answer is nuanced. While Cladribine (brand name Mavenclad) isn't on the FDA's official drug shortage list as of early 2026, many patients experience real delays and difficulty getting their prescriptions filled.

Here's what's actually going on — and what you can do about it.

Is Cladribine Still in Shortage?

Technically, Mavenclad (oral Cladribine tablets) is not in a formal FDA shortage as of March 2026. The brand-name product from EMD Serono is being manufactured and distributed through specialty pharmacies.

However, the injectable form of Cladribine (sold as Leustatin and as generics for hairy cell leukemia) has had a history of intermittent supply disruptions dating back to the mid-2010s. These shortages are related to limited manufacturers and the relatively small patient population for hairy cell leukemia.

For MS patients, the access challenges with Mavenclad are less about manufacturing shortages and more about the specialty pharmacy distribution system, insurance requirements, and coordination delays.

Why Is Cladribine Hard to Find?

Even without a formal shortage, several factors make Cladribine difficult to access in 2026:

Specialty Pharmacy Bottlenecks

Mavenclad is only available through specialty pharmacies — not your local retail pharmacy. These pharmacies require prescriber enrollment, patient intake forms, and often coordinate directly with insurance. This adds days or weeks to the process.

Insurance Gatekeeping

Nearly all insurance plans require prior authorization for Cladribine. Many also mandate step therapy, meaning you must try and fail on at least one or two other MS medications first. If documentation is incomplete, authorizations are denied, creating further delays.

Limited Prescribers

Cladribine is primarily prescribed by MS-specialist neurologists. If you're in a rural area or don't have easy access to an MS center, getting prescribed Cladribine in the first place may be the biggest hurdle. For help, see our guide on finding a doctor who can prescribe Cladribine.

High Cost Triggering Extra Review

At a list price of approximately $99,500 per annual treatment course, Cladribine triggers heightened review from insurance companies, pharmacy benefit managers, and specialty pharmacies — all of which slow down the process.

What Does Cladribine Cost in 2026?

Here's a breakdown of current pricing:

• Brand-name Mavenclad: Approximately $99,500 per annual course ($190,000+ for the full 2-year treatment) at list price
• Generic Cladribine tablets: Approved November 2025 (Apotex Inc.). Early pricing estimates range from $15,000-$22,000+ per course, though this may decrease as availability expands
• IV Cladribine (for leukemia): Approximately $300-$7,800 per course depending on generic availability
• With insurance + copay assistance: Many commercially insured patients pay $0-$25 per course through EMD Serono's Mavenclad Co-pay Program

For detailed savings strategies, visit our complete guide to saving money on Cladribine.

New Options in 2026

Generic Cladribine Tablets

The biggest development for Cladribine access is the FDA approval of generic Cladribine tablets in November 2025. Manufactured by Apotex Inc., this generic has the potential to improve supply, increase competition, and — over time — reduce costs. It's still early days for distribution, but patients should ask their specialty pharmacy about generic availability.

Improved Specialty Pharmacy Coordination Tools

Tools like Medfinder are making it easier for patients to locate medications in stock, cutting down on the phone calls and uncertainty. If you're struggling to find Cladribine, Medfinder can show you which pharmacies have it available.

How to Find Cladribine in Stock

Here's a step-by-step approach:

1. Ask your doctor to submit the prior authorization early — ideally 3-4 weeks before your treatment cycle is scheduled to begin.
2. Check Medfinder to find pharmacies with Cladribine in stock.
3. Call MS LifeLines (1-800-283-8088) for help coordinating with specialty pharmacies and navigating insurance.
4. Ask about the generic — it may be available through different specialty pharmacy channels.
5. Contact the National MS Society (1-800-344-4867) if you're stuck. Their MS Navigators can help troubleshoot access issues.

For more detailed strategies, read our full guide on how to find Cladribine in stock near you.

Final Thoughts

Cladribine isn't technically in shortage — but for many patients, it sure feels like it. The combination of specialty pharmacy distribution, insurance barriers, limited prescribers, and high cost creates a real access gap. The good news is that the 2025 generic approval, manufacturer support programs, and new patient tools are making things better.

If you're waiting on Cladribine, don't wait in silence. Use the resources above, stay in close contact with your doctor's office, and remember that you have the right to appeal insurance denials. Your MS treatment matters, and there are people and tools ready to help you access it.